European Journal of Nuclear Medicine and Molecular Imaging

Article	Citations
“Fuzzy” radiomics: the way forward for nuclear medicine imaging applications?	383
Towards molecular imaging-guided intervention theatres in oncology	259
Tumor agnostic ultrasmall nanoprobes for fluorescence-guided surgical resection in peritoneal metastasis	187
Intriguing information from recent letter and article regarding unwanted targeting of salivary glands by PSMA ligands	181
A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients	152
Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma	130
New horizons for the World Federation of Nuclear Medicine and Biology: achievements, partnerships, and future directions	113
Cadherin-17 as a target for the immunoPET of adenocarcinoma	101
Nuclear imaging and therapy in oncology in Poland in 2021–2022	91
Variabilities in global DNA methylation and β-sheet richness establish spectroscopic landscapes among subtypes of pancreatic cancer	91
FAPI PET for monitoring of rheumatological treatment in multifocal peritoneal nodular fibrosis: a case study	89
Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review	84
Correction to: Preclinical SPECT and PET: Joint EANM and ESMI procedure guideline for implementing an efficient quality control programme	77
Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangli	66
[68Ga]Ga-FAPI versus [18F]FDG PET/CT in the evaluation of Langerhans cell histiocytosis	65
Prospective clinical study of sentinel node detection in bladder cancer using a hybrid tracer – Towards replacement of pelvic lymph node dissection in cases with sentinel node visualization on SPECT/C	65
The feasibility of quantitative assessment of dynamic 18F-fluorodeoxyglucose PET in Takayasu’s arteritis: a pilot study	62
Cinematic rendering of [18F]FDG-PET/MR	60
First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2	56
Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus	56
Robust and generalizable artificial intelligence for multi-organ segmentation in ultra-low-dose total-body PET imaging: a multi-center and cross-tracer study	55
[18F]FDG PET/MR to assess disease extension and inflammation in children and young adults with primary ciliary dyskinesia	55
Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation	54
68Ga-FAPI and 18F-FDG PET/CT for predicting pathologic response and progression-free survival in locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy	54
Simultaneous high-resolution whole-brain MR spectroscopy and [18F]FDG PET for temporal lobe epilepsy	52

Avid 18F-FDG uptake of benign gastric-type intraductal papillary mucinous neoplasm of the pancreas	52
Seasonal variation in D2/3 dopamine receptor availability in the human brain	52
Persistent lung and vascular inflammation in mild to moderate COVID-19 survivors detected by ¹⁸F-FDG PET/CT: A quantitative imaging study with implications for cardiovascular risk	51
Tracking macrophages by direct and indirect 89Zr PET imaging	51
[18F]Fluorocholine PET/MRI and [18F]Fluorocholine PET/CT as first- and second-line imaging in primary hyperparathyroidism – who takes the lead?	51
Sex-specific differences in patients with differentiated thyroid carcinoma and their possible impact on survival	51
Long-term impact of myocardial inflammation on quantitative myocardial perfusion—a descriptive PET/MR myocarditis study	51
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial	50
Individual-level metabolic connectivity from dynamic [18F]FDG PET reveals glioma-induced impairments in brain architecture and offers novel insights beyond the SUVR clinical standard	50
Prospective pilot study with [89Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE)	50
Deep learning–based whole-body characterization of prostate cancer lesions on [68Ga]Ga-PSMA-11 PET/CT in patients with post-prostatectomy recurrence	50
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer	50
Dynamic frame-by-frame motion correction for 18F-flurpiridaz PET-MPI using convolution neural network	50
Combination therapy of an 211At-labeled RGD peptide and immune checkpoint blockade to enhance antitumor efficacy	49
FAPI PET/CT in infectious, inflammatory, and rheumatological diseases: “watch it like a hawk” or “one swallow does not make a summer”?	48
Preclinical development of [18F]TAAR1-2203 as a PET radioligand for imaging TAAR1 expression and receptor occupancy	48
Real-time diagnosis of sampled lesions in targeted biopsy of prostate Cancer using a novel tracer [64Cu] Cu-DOTA-PSMA-3Q: a pilot preclinical study	48
TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET/CT images — a multi-center generalizability analysis	48
Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617	48
Enhancing interpretability of AI with radiomics-based deep neural network: proof of concept in the classification of Parkinsonian syndromes with 18F-FDG PET imaging	48
Vancomycin-based tracers guiding in situ visualization of bacteria on osteosynthesis devices and surgical debridement	47
PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma patients, results of a prospective study	47
Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group	46
Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma	45
Assessment of [18F]PI-2620 Tau-PET Quantification via Non-Invasive Automatized Image Derived Input Function	44
PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer	44
Brain perfusion estimation by Tikhonov model-free deconvolution in a long axial field of view PET/CT scanner exploring five different PET tracers	44
Abdelhamid H. Elgazzar, Synopsis of Pathophysiology in Nuclear Medicine, Second Edition	43
Sentinel lymph node detection in thyroid carcinoma using [68Ga]Ga-tilmanocept PET/CT: a proof-of-concept study	43
Diffusely increased breast uptake of [18F]AlF-NOTA-FAPI-04 related to menstrual status in a patient with papillary thyroid cancer	43
Abnormal localized [18F]FDG accumulation in a Hoffman 3D brain phantom caused by Pseudomonas aeruginosa and Stenotrophomonas maltophilia	43
Updated practice guideline for dual-energy X-ray absorptiometry (DXA)	43
Preclinical evaluation and pilot clinical study of [68Ga]Ga-NOTA-H006 for non-invasive PET imaging of 5T4 oncofetal antigen	42
Bilateral intense [68 Ga]Ga-PSMA‑11 uptake in cyproterone acetate induced gynecomastia	42
[18F]-mFBG imaging for COVID-19-induced cardiac sympathetic innervation impairment	41
Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography	41
Parkinson’s Disease-Related pattern in isolated REM sleep behaviour disorder as a prodromal progression marker: 8-Year Follow-Up changes assessed at three time points	41
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin’s lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgk	41
Validation of simplified uptake measures against dynamic Patlak Ki for quantification of lesional 89Zr-Immuno-PET antibody uptake	40
Moganshan international consensus on further strengthening global scientific collaboration in the field of molecular imaging	40
Atypical [18F]FDG avidity in ALK-positive anaplastic large cell lymphoma: diagnostic and monitoring potential of [18F]FAPI PET/CT	40
Advancements in non-invasive visualization of the immune checkpoint TIGIT: a systematic review	40
Distinguishing benign lesions from malignant ones using FAPI-based tracers: will we need to bid farewell to dual-time points imaging?	39
PSMA-targeted radioligand therapy with [177Lu]Lu-LNC1011 for metastatic castration-resistant prostate cancer: a pilot study	39
Assessment of cerebral drug occupancy in humans using a single PET-scan: A [11C]UCB-J PET study	39
Intense [68Ga]Ga-FAPI-04 uptake of pancreatic microcystic serous cystadenoma mimicking malignancy	39
Promise of hypoxia-targeted tracers in metastatic lymph node imaging	39
[68Ga]Ga-Pentixafor PET/CT for Durie-Salmon PLUS staging and risk stratification in newly diagnosed multiple myeloma	39
Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside	39
Correction to: A bis-boron boramino acid PET tracer for brain tumor diagnosis	39

A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [68Ga]Ga-PSMA-11 total-body PET/CT imaging	38
Synthesis, preclinical evaluation, and clinical translation of [68Ga]Ga-Asp2-JR11, a SSTR2 antagonist for PET imaging of neuroendocrine neoplasms	38
Correction to: Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993	38
Comparative assessment of radiation therapy–induced vasculitis using [18F]FDG-PET/CT in patients with non-small cell lung cancer treated with proton versus photon radiotherapy	38
Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [68Ga]Ga-PSMA-11 PET scans of primary prostate cancer	38
Identifying and navigating bottlenecks in the translation of novel radiopharmaceuticals: a perspective	38
Diagnostic performance of 18F-FDG PET/CT in the prediction of axillary lymph node metastasis in Luminal A breast cancer	38
Development of STING probes and visualization of STING in multiple tumor types	37
Ternary classification prediction and heterogeneity quantification for HER2-Zero, -low, and -positive in breast cancer using HER2-targeted PET/CT imaging	37
STING-targeted PET tracer for early assessment of tumor immunogenicity in colorectal cancer after chemotherapy	37
A distinctive “Shotgun-like” 18F-FDG PET uptake pattern in disseminated cutaneous sarcoidosis responding to TNFα inhibitors	36
[68Ga]Ga-DOTA-FAPI-04 PET/CT depicts metastases from medullary thyroid cancer that [68Ga]Ga-DOTATOC PET/CT missed	36
Differential Vascular Response to Corticosteroid Therapy in Takayasu Arteritis Revealed by Serial FDG-PET Imaging	36
PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus	35
CSF proteomic pathway alterations and caudate dopamine transporter deficits predict cognitive vulnerability in early Parkinson’s disease	34
[68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors	34
Preclinical and first‑in‑human evaluation of [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging to assess tumor PD-L1 expression	34
Lisa Bodei, Jason S. Lewis, Brian M. Zeglis (Editors): Radiopharmaceutical Therapy	34
Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)	34
Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review	34
A cutting-edge technology for the future of nuclear medicine	34
[68Ga]Ga-P16-093 PET/CT in newly diagnosed prostate cancer: Histopathological validation and comparison with [68Ga]Ga-PSMA-11	33
Smoking reshapes systemic metabolic coordination across lung cancer subtypes: a multicenter total-body 18F-FDG PET/CT study with tumor habitat imaging	33
Increased incidence of primary metastatic prostate cancer in the era of PSMA PET/CT: a population-based analysis	33
Interpretable multimodal deep learning model for predicting post-surgical international society of urological pathology grade in primary prostate cancer	33
Multi-modality deep learning-based [68Ga]Ga-DOTA-FAPI-04 PET polar map generation: potential value in detecting reactive fibrosis after myocardial infarction	33
Comparison of two hybrid sentinel node tracers: indocyanine green (ICG)-99mTc-nanocolloid vs. ICG-99mTc-nanoscan from a nuclear medicine and surgical perspective	33
Imaging biomarkers of cortical neurodegeneration underlying cognitive impairment in Parkinson’s disease	33
About ESTMABLE2: non-inferiority doesn’t equal better	33
Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993	33
Molecular radiotherapy for adult type metastatic neuroendocrine tumours in children	33
Diagnostic accuracy of PSMA-targeted radioguided surgery in prostate cancer at multiple anatomical levels: a systematic review and meta-analysis	32
Intraoperative molecular imaging of colorectal lung metastases with SGM-101: a feasibility study	32
Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study	32
Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [169Yb]Yb2O3 nanoseeds	32
Guiding principles on the education and practice of theranostics	32
An artificial intelligence-driven image quality assessment system for whole-body [18F]FDG PET/CT	32
Exploratory evaluation of early 68Ga-FAPI-46 PET/CT volume-based parameters in systemic sclerosis-associated interstitial lung disease	31
From image reconstruction to clinical prognosis: A comprehensive analysis of centiloid-based amyloid PET assessment	31
Hypermetabolic pulmonary lesions detection and diagnosis based on PET/CT imaging and deep learning models	31
Quantitative 18F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST	31
A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients	31
Beyond DOTATATE: [68Ga]NODAGA-LM3 PET/CT unmasks the culprit tumor in tumor-induced osteomalacia	31
Radiofrequency ablation for autonomously functioning nodules as treatment for hyperthyroidism: subgroup analysis of toxic adenoma and multinodular goitre and predictors for treatment success	31
Multicentric development and evaluation of [18F]FDG PET/CT and CT radiomic models to predict regional and/or distant recurrence in early-stage non-small cell lung cancer treated by stereotactic body r	31
Impact of extended [177Lu] Lu-PSMA-617 therapy on absorbed kidney dose and CKD-EPI values: how long can therapy be safely continued?	31
Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer	31
Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry	31
The diagnostic performance of [18F]Florbetazine in Alzheimer’s disease: a head-to-head comparison to [11C]PiB and [18F]Florbetapir	31
Distinct metabolic patterns of neuropsychiatric systemic lupus erythematosus on hierarchical cluster analysis	30
Reply to Vaz et al., Editorial Commentary: Should “Heterogeneous response” be considered as new category for assessing treatment response in patients with breast cancer?	30
First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy	30
Non-invasive molecular imaging for precision diagnosis of metastatic lymph nodes: opportunities from preclinical to clinical applications	30
Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas	30
Amyloid pathology related to aberrant structure-function coupling of brain networks in Alzheimer’s disease: insights from [18F]-florbetapir PET imaging	30
Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy	30
Molecular imaging: The bridge from human phenome to personalized precision medicine	30
Efficacy of peptide receptor radionuclide therapy in patients with oligodiscordant gastroenteropancreatic neuroendocrine tumours	30
Disrupted gut microecology after high-dose 131I therapy and radioprotective effects of arachidonic acid supplementation	30
Intelligent ultrafast total-body PET for sedation-free pediatric [18F]FDG imaging	30
Forearm metastasis as solitary manifestation of recurrent prostate cancer: A challenge for standard PSMA PET imaging protocol	30
Pre-operative dual-time-point [18F]FET PET differentiates CDKN2A/B loss and PIK3CA mutation status in adult-type diffuse glioma: a single-center prospective study	29
Radioembolization of hepatocellular carcinoma with 90Y glass microspheres: an earlier administration day unexpectedly improves tumour control probability	29
Association of PET vascular activity score with Takayasu’s arteritis angiographic progression	29
Development and characterisation of [18F]TTDP, a novel T cell immunoglobulin and ITIM domain tracer, in humanised mice and non-human primates	29
Bone marrow scintigraphy as a prognostic marker of overall survival in mCRPC patients treated with Radium-223 dichloride	29
Pre-symptomatic scintigraphic and genetic cascade screening in cardiac transthyretin amyloidosis	29
Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging	28
Machine learning predictive performance evaluation of conventional and fuzzy radiomics in clinical cancer imaging cohorts	28
European guidelines update on PSMA PET/CT for prostate cancer staging—snap back to reality	28
Correction to: Deep learning for improving PET/CT attenuation correction by elastic registration of anatomical data	28
Visual grading for noninvasive assessment of transthyretin-related cardiomyopathy with bone scintigraphy: time for moving forward?	28
Correction to: [18F]FDG brain PET findings in CLIPPERS at diagnosis and therapeutic follow-up	28
Assessing non-invasive quantitative methods for [18F]SynVesT-1 PET imaging of synaptic vesicle glycoprotein 2A in the rat brain	28
Commentary to “[68 Ga]Ga-FAPI-04 PET/CT on assessing Crohn’s disease intestinal lesions” by Chen and colleagues	28
[177Lu]Lu-FAP-2286 therapy in ovarian neuroendocrine carcinoma: a promising theranostic approach	28
A rationally designed nuclei-targeting FAPI 04-based molecular probe with enhanced tumor uptake for PET/CT and fluorescence imaging	28
Extended nodal radiotherapy for prostate cancer relapse guided with [11C]-choline PET/CT: ten-year results in patients enrolled in a prospective trial	27
Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging	27
Prognostic role of metabolic parameters (MTV and TLG) of staging PET/CT in the pediatric population with Hodgkin’s lymphoma: an open discussion	27

Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?	27
¹⁸F-AlF-NOTA-octreotide PET/CT in high-grade G3 neuroendocrine tumors and neuroendocrine carcinomas: diagnostic performance and complementarity with ¹⁸F-FDG PET/CT	27
Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer	27
First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm	26
Exploring the value of FAP-targeted PET/CT in differentiating breast cancer molecular subtypes: a preliminary study	26
Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer’s disease	26
CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology	26
Comparative analysis of [18F]F-FAPI PET/CT, [18F]F-FDG PET/CT and magnetization transfer MR imaging to detect intestinal fibrosis in Crohn’s disease: A prospective animal model and human cohort study	26
Clinical added value of LAFOV PET/CT in patients undergoing same-day [18 F]FDG SAFOV PET/CT scans: an initial experience report and explorative study	26
Quantitative dual-tracer PET/CT biomarkers correlate concordant lesion uptake with PSMA-RLT outcomes in mCRPC: a dual-center study	26
Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma	26
Comparison of mCRPC [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting	26
PET molecular imaging of in vivo brain metabolism, synaptic density and glial reactivity changes after neural stem cell transplantation on a rat model of ischemic stroke	26
PET imaging of new target CDK19 in prostate cancer	26
The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer	26
Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication	26
Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images	26
Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study	25
Pyomyositis, a rare complication of a urinary tract infection on FDG PET/CT	25
Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry	25
Comparisons of treatment performance and therapy sequences in neuroendocrine neoplasms using progression-free survival ratios	25
Targeted alpha therapy: a comprehensive analysis of the biological effects from “local-regional-systemic” dimensions	25
[99mTc]Tc-sestamibi SPECT/CT for the diagnosis of kidney tumours: a multi-centre feasibility study (MULTI-MIBI Study)	25
A comparative study of [68Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in the diagnostic accuracy and resectability prediction of ovarian cancer	25
Longitudinal renal function following [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancer	25
Comparison of the diagnostic value of [68 Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in patients with T stage ≤ 2a2 uterine cervical cancer: a prospective study	25
PET imaging utilization and trends in Germany: a comprehensive survey	25
The first international network symposium on artificial intelligence and informatics in nuclear medicine: “The bright future of nuclear medicine is illuminated by artificial intelligence”	25
PET/CT with [68Ga]Ga-TEoS-DAZA for localization of a traumatic biliary leak	25
Collection on molecular imaging in cardiac amyloidosis	24
Expert consensus on workflow of PET/CT with long axial field-of-view	24
New thresholds in semi-quantitative [18F]FDG PET/CT are needed to assess large vessel vasculitis with long-axial field-of-view scanners	24
Correction to: Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate	24
PSMA-targeted theranostics of solid tumors: applications beyond prostate cancers	24
DICOM header editing, between possibilities and regulatory bounds– 40 years of DICOM “standard”	24
PET scout: A valuable technology in pediatric 18F-FDG PET/CT imaging	24
Interpretive consistency of a qualitative 68Ga-PSMA PET framework for treatment response assessment in hepatocellular carcinoma: a head-to-head comparison with cross-sectional imaging	24
Beyond 68Ga-labeled somatostatin analogues: is it time to say goodbye to [68Ga]DOTA-conjugated peptides for neuroendocrine neoplasms?	24
Correction to: Modelling [18F]LW223 PET data using simplified imaging protocols for quantification of TSPO expression in the rat heart and brain	24
Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis	24
Subendocardial quantification enhances coronary artery disease detection in 18F-flurpiridaz PET	23
Remarkable response after cocktail therapy with 177Lu-PSMA and 177Lu-DOTA-IBA in the treatment of mCRPC	23
Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020	23
The confounding effects of microvascular physiology on the uptake and diagnostic accuracy of [18F]fluoroethyl-tyrosine positron emission tomography in gliomas	23
Impact of deep learning denoising on kinetic modelling for low-dose dynamic PET: application to single- and dual-tracer imaging protocols	23
Multidisciplinary team interpretation performance for indeterminate bone uptake on PSMA PET during prostate cancer staging: Comparison with PROMISE criteria	23
Multimodal glyco-lipid-EBVDNA signature prognostic model for individualized risk stratification of locally advanced nasopharyngeal carcinoma	23
Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: considerations on clinical safety profiles	22
Safety and efficacy of [177Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer	22
The eye-black sign of lower eyelids related to R-CHOP therapy: a rare imaging pitfall	22
Exploring the metabolic landscape of lung adenocarcinoma and squamous cell carcinoma: a total-body [18F]FDG PET/CT approach	22
PET imaging of atherosclerotic plaques using the stabilin-2-targeted tracer 18F-S2P in preclinical models	22
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study	22
Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AI	22
Fibroblast activation Protein-Targeted PET/CT using [18 F]FAP-2286 for the evaluation of lung cancer: A comparative study with [18 F]FDG PET/CT	22
Preoperative assessment of pancreatic cancer with [68Ga]Ga-DOTA-FAPI-04 PET/MR versus [18F]-FDG PET/CT plus contrast-enhanced CT: a prospective preliminary study	22
FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis	22
Comprehensive analysis of [18F]MFBG biodistribution normal patterns and variability in pediatric patients with neuroblastoma	22
PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington’s disease	22
Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology	22
Long axial field of view (LAFOV) PET-CT: implementation in static and dynamic oncological studies	22
Impact of Tafamidis on [99mTc]Tc-pyrophosphate Scintigraphy in Ala97Ser Hereditary Transthyretin amyloid cardiomyopathy: significant initial reduction with stable Long-Term effects	22
Cholangio-PET/CT with [68Ga]Ga-TEoS-DAZA for bile leak localisation after hepatobiliary surgery	22
Fully automated spleen segmentation predicts progression-free survival in HCC patients following transarterial radioembolization	22
Rapid dynamic acquisition of cardiac amyloid radionuclide imaging	22
Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility study	21
Pleasurable music activates cerebral µ-opioid receptors: a combined PET-fMRI study	21
Targeting tumour surface collage with hydrogel probe: a new strategy to enhance intraoperative imaging sensitivity and stability of bladder cancer	21
LiDAR-registered freehand SPECT combined with NIR-fluorescence enables spatial localisation of tracer-avid inguinal lymph nodes: A clinical feasibility study	21
In vivo methods for imaging blood–brain barrier function and dysfunction	21
The value of serial [⁶⁸Ga]Ga-FAPI-04 PET/CT in predicting pathological response and evaluating therapeutic efficacy to neoadjuvant chemotherapy in breast cancer	21
18F-sodium fluoride PET-CT visualizes both axial and peripheral new bone formation in psoriatic arthritis patients	21
Chlorin e6-loaded goat milk-derived extracellular vesicles for Cerenkov luminescence-induced photodynamic therapy	21
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours	21
Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics	21
The predictive role of [177Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis	21
Bridging the gap to clinical translation: the advanced role of PET molecular imaging in stem cell therapy	21
Role of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis	21
Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis	21
Efficacy of combined targeted radionuclide therapy and immune checkpoint Inhibition in animal tumour models: a systematic review and meta-analysis of the literature	21
Neoadjuvant alpha peptide receptor radionuclide therapy for a patient with a pulmonary carcinoid	21
The prognostic significance of TSPO-PET imaging in IDH-mutant glioma: a single-center, retrospective study	21
Myocardial flow reserve derived from D-SPECT for evaluating non-culprit ischemic lesions in STEMI patients: comparison with quantitative flow ratio	20
New opportunities for dosimetric approach in patients with differentiated thyroid cancer	20
James F. Griffith. Diagnostic ultrasound: musculoskeletal, 3rd edition. Elsevier, 2025, ISBN: 9780443285646	20
Establishing normal myocardial blood flow and myocardial flow reserve values: a rubidium-82 positron emission tomography study	20
Connectivity based on glucose dynamics reveals exaggerated sensorimotor network coupling on subject-level in Parkinson’s disease	20
Radioligand therapy of pancreatic ductal adenocarcinoma using an αvβ6-integrin targeting 68Ga / 177Lu labeled theranostic pair	20
Image fraud in nuclear medicine research	20
[177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data	20
PET imaging of animal models with depressive-like phenotypes	20
Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models	20
Letter to the Editor: Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer	20
FAP inhibitors: are we really using the best method to evaluate the residence time?	20
Lymph node classification in E-PSMA reporting guidelines for PSMA-PET	20